Tarsus Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated June 13, 2024, details the results of the Annual Meeting of Stockholders held by Tarsus Pharmaceuticals, Inc. on that date. The Company is incorporated in Delaware and its common stock trades on the Nasdaq Global Select Market under the symbol "TARS".
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The report focuses exclusively on corporate governance matters.
Material Changes and Voting Results
At the record date of April 15, 2024, the Company had 37,776,665 shares of common stock outstanding. A quorum was established with 31,978,938 shares present. Two proposals were submitted and approved:
- Election of Directors: Two Class I director nominees were elected to serve until the 2027 annual meeting:
- Bhaskar Chaudhuri, Ph.D.: 21,766,101 votes for; 2,941,857 votes withheld.
- William J. Link, Ph.D.: 20,817,032 votes for; 3,890,926 votes withheld.
- Ratification of Auditors: Stockholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
- Votes For: 31,896,705
- Votes Against: 24,949
- Abstain: 57,284
Guidance, Outlook, and Risks
The filing does not provide management commentary, financial guidance, outlook, or specific risk factors. It serves solely to disclose the outcome of the shareholder vote.
Key Facts for Investor Verification
- Confirmation that Bhaskar Chaudhuri and William J. Link have officially joined the Board of Directors for the Class I term.
- Verification of the continued engagement of Ernst & Young LLP as the external auditor for the 2024 fiscal year.
- Review of the definitive proxy statement filed on April 26, 2024, for detailed background on the director nominees and auditor selection.